Subsense, a developer of non-surgical invasive, nanoparticle-based brain-computer interfaces (BCIs), has added $10 million in new capital following positive early breakthroughs, bringing total funding to $27 million. The investment from Golden Falcon Capital will accelerate research and development in nanoparticle sensing, in vivo biosafety programs, next-generation nanoparticle design, and hardware miniaturization.

Subsense is a neurotechnology company developing the first non-surgical, nanoparticle-based bidirectional brain-computer interface. Subsense is partnered with leading global neurological research institutions. The company is venture-backed with its global headquarters in Palo Alto, California and was co-founded by neurotech entrepreneur Tetiana Aleksandrova.